US stock futures flounder amid tech weakness, Fed caution
Investing.com - Mizuho (NYSE:MFG) has raised its price target on Gilead Sciences (NASDAQ:GILD) to $131.00 from $117.00 while maintaining an Outperform rating on the stock. The biotech giant, currently trading near its 52-week high with a market cap of $147 billion, has demonstrated strong momentum with a 66% return over the past year. According to InvestingPro data, eight analysts have recently revised their earnings estimates upward.
The price target increase is primarily driven by higher sales estimates for anito-cel, Gilead’s treatment for relapsed/refractory multiple myeloma. Mizuho now models approximately $6 billion in peak worldwide unadjusted end-user sales for the therapy, up from its previous estimate of $3.4 billion.
Mizuho noted that anito-cel’s potential launch is expected in 2026 for fourth-line and later treatment, with possible earlier line indications to follow. The firm described the opportunity as "substantial, eventually."
The analysis also now includes Yeztugo, which was approved on June 18, 2025, within Gilead’s HIV base business rather than its pipeline. Mizuho models approximately $8 billion in worldwide peak unadjusted sales for Yeztugo, higher than the consensus estimate of about $5 billion.
Mizuho now projects approximately 3% growth for Gilead’s HIV business in 2025, in line with the company’s updated guidance, while noting that Gilead’s HIV launches have historically been underestimated.
In other recent news, Gilead Sciences reported a strong second-quarter performance, leading to several adjustments in stock price targets by major financial firms. Gilead’s total sales reached $7.1 billion, with earnings per share at $1.97, positioning between consensus estimates and BofA’s forecasts. Following these results, BofA Securities raised its price target to $140 while maintaining a Buy rating. Morgan Stanley (NYSE:MS) also increased its target to $143, citing robust performance in the HIV segment. RBC Capital adjusted its target to $98, noting strong results in key franchises despite some underperforming areas. TD Cowen increased its target to $115, highlighting a 3% EPS beat driven by HIV sales. Cantor Fitzgerald reiterated an Overweight rating and noted Gilead’s raised full-year revenue guidance by $500 million, excluding its COVID-19 treatment Veklury. These developments reflect analysts’ confidence in Gilead’s financial health and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.